Navigation Links
Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer

MUMBAI, India, Aug. 13 /PRNewswire/ -- Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN PHARMA, BSE: 524715) today announced that on August 13, 2008, the U.S. Federal Trade Commission (FTC) granted early termination of the antitrust waiting period under the Hart-Scott-Rodino Act (HSR) for the previously announced Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. (Alkaloida), a subsidiary of Sun Pharma, for all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. (Taro). Clearance under HSR meets one of the conditions to the Tender Offer. The Offer is scheduled to expire at 5:00 p.m., New York City time, on Tuesday, September 2, 2008 unless extended.

The Offer was commenced on June 30, 2008 in order to comply with the terms of the Option Agreement between Alkaloida and the controlling shareholders of Taro. The complete terms and conditions are set out in the Offer to Purchase, which is filed with the U.S. Securities and Exchange Commission. Taro shareholders may obtain copies of all of the offering documents, including the Offer to Purchase, free of charge at the SEC's website ( or by directing a request to MacKenzie Partners, Inc., the Information Agent for the offer, at 105 Madison Avenue, New York, New York 10016, (212) 929-5500 (Call Collect) or Call Toll-Free (800) 322-2885, Email:

Greenhill & Co., LLC is acting as the Dealer Manager for the Tender Offer and MacKenzie is acting as the Information Agent for the Tender Offer.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, U.S. and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at


Uday Baldota Mira Desai

Tel +91 22 6645 5645, Xtn 605 Tel +91 22 6645 5645, Xtn 606

Tel Direct +91 22 66455605 Tel Direct +91 22 66455606

Mobile +91 98670 10529 Mobile +91 98219 23797

E mail E mail

Brunswick Group for Sun Pharma MacKenzie Partners

Nina Devlin / Erin Becker Robert Marese

+1 212 333 3810 +1 212 929 5500

Arad Communications for Sun Pharma Greenhill

Gali Dahan Ashish Contractor

+972 3 7693320 +1 212 389 1537

SOURCE Sun Pharmaceutical Industries Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Announces Second Quarter 2008 Results
2. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
3. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
4. Employee Involvement Is Key to Long-Term Pharmacy Cost Control, Finds Buck Consultants Survey
5. MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
6. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
7. KV Pharmaceutical Company Reports Fiscal 2009 First Quarter Results
8. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
9. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
10. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
11. IntelliPharmaCeutics Provides Update on Activities
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (ASI) as their exclusive channel partner for the Nutraceutical Specialties products into oral ... the US, effective immediately. , “We are pleased to announce our expanded ...
(Date:11/30/2015)... ... 2015 , ... Medicalis, a leading developer of enterprise-scale Imaging ... (RSNA) annual meeting, being held November 29 – December 3, 2015, that its ... company has completed installations for Integrated Delivery Network (IDN) customers such as WellSpan, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and ... Mesh technology for soft tissue repair in the US via Insightra’s national direct ... surgical mesh intended to support and reinforce soft tissue for 6-9 months before ...
(Date:11/30/2015)... ... ... TransPack Volume 6 features 30 customizable transitions created exclusively for use within ... with blur & drop shadow options. Utilize the controls in the inspector window ... the next with TransPack's easily customizable styles. , TransPack Volume 6 features ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015  Hanger, Inc. (NYSE: ... restatement of the terms of its previously announced consent ... to its $200,000,000 aggregate principal amount 7⅛% Senior Notes ... (i) the consent fees payable pursuant to the Consent ... Notes and (iii) the expiration date of the Consent ...
(Date:11/30/2015)...  Precision Image Analysis Inc. (PIA), a leading ... a dramatic expansion of its capabilities as a ... ISO-9001:2008 certification for its Quality Management System, PIA ... and procedures. This expansion enables PIA to support ... Lab services include design and optimization of protocols, ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. 30, ... company focused on acquiring and developing innovative therapies for ... appointment of Keith A. Katkin as chairman ... J. Flesher , chief executive officer for OticPharma, Ltd.  ... organizations.  As chairman, he will be able to share ...
Breaking Medicine Technology: